Second opinion for HP slide

Blood

Report in 48Hrs

At Home

No Fasting Required

Details

Review of histopathology.

₹296₹423

30% OFF

Second Opinion for HP Slide - Comprehensive Medical Test Information Guide

Why is it done?
- A second opinion for Helicobacter pylori (HP) slide examination provides an independent microscopic review and verification of gastric biopsy specimen analysis
- Primary indications include: Discordant or inconclusive initial HP test results, diagnostic uncertainty regarding infection status, confirming presence or absence of H. pylori bacteria in gastric tissue samples
- Evaluation of atypical or ambiguous morphologic findings that may represent H. pylori organisms or mimicking artifacts
- Typically performed when initial pathology examination yields equivocal results or when clinical suspicion remains high despite negative initial findings
- Assessment of therapeutic efficacy when evaluating post-treatment biopsies to confirm successful H. pylori eradication
- Quality assurance and validation in histopathology departments for educational and diagnostic accuracy purposes
Normal Range
- Normal result (Negative): Absence of Helicobacter pylori organisms visible on microscopic examination of gastric tissue biopsy slides
- No curved, gram-negative bacilli morphologically consistent with H. pylori identified in gastric mucosa or submucosa
- Abnormal result (Positive): Identification of H. pylori organisms on histologic examination with specific morphologic and staining characteristics
- Semiquantitative grading when present: Rare (+1), Few (+2), Moderate (+3), or Numerous (+4) organisms
- Borderline/Uncertain: Presence of morphologically atypical forms, degenerated organisms, or structures with equivocal features requiring expert review
- Specimen adequacy assessment: Confirmation that adequate gastric mucosa sampling was obtained for reliable diagnostic interpretation
Interpretation
- Negative result with high confidence: No H. pylori organisms identified on careful microscopic examination; patient likely does not have active H. pylori infection at time of biopsy
- Positive result with high confidence: H. pylori organisms definitively identified with characteristic morphology; patient has active H. pylori infection
- Organisms quantification significance: Higher bacterial loads (+3 to +4) correlate with more active inflammation; lower loads (+1 to +2) may occur post-treatment or with chronic infection
- Discordant results interpretation: If second opinion differs from initial report, review both slides systematically; consider additional staining methods (immunohistochemistry, special stains like Giemsa or silver stains)
- False-negative factors: Patchy organism distribution, recent antibiotic use, achlorhydria, intestinal metaplasia, or inadequate biopsy sampling locations
- False-positive considerations: Morphologic mimics including other spiral bacteria, artifacts, or cellular inclusions; immunohistochemistry confirmation may be warranted
- Associated gastric inflammation: Assess concurrent findings including chronic active gastritis, intestinal metaplasia, atrophy, and dysplasia that indicate H. pylori disease severity
- Sydney classification application: Report should include location (antrum, body, fundus), inflammation, activity, atrophy, intestinal metaplasia, and H. pylori density
Associated Organs
- Primary organ: Stomach (gastric mucosa) - particularly antrum and fundus where H. pylori preferentially colonizes
- Duodenum: H. pylori can migrate to duodenal mucosa causing duodenitis and ulceration in some patients
- Associated gastric conditions: Chronic gastritis, peptic ulcer disease, gastric adenocarcinoma, mucosa-associated lymphoid tissue (MALT) lymphoma
- Systemic associations: Iron deficiency anemia, vitamin B12 deficiency, thrombocytopenia, autoimmune diseases
- Pathologic consequences: Increased risk of gastric cancer (intestinal type), lymphoma development, and progressive gastric atrophy with chronic untreated infection
- Potential complications: Perforation from severe ulceration, hemorrhage from erosive disease, gastric outlet obstruction from scarring
Follow-up Tests
- Immunohistochemistry staining: Antibody-based detection to confirm morphologically equivocal H. pylori organisms with high specificity
- Special histologic stains: Giemsa stain, Gram stain, or silver stains (Warthin-Starry) for enhanced visualization and confirmation
- Repeat endoscopy with biopsy: If clinical suspicion remains high and second opinion contradicts initial findings, consider rebiopsy from different gastric regions
- Non-invasive confirmatory tests: Urea breath test (UBT), stool antigen testing, or serology (IgG antibodies) if tissue diagnosis remains inconclusive
- Post-treatment verification: Repeat biopsy at least 4 weeks after antibiotic therapy completion to confirm successful H. pylori eradication
- Ancillary pathology evaluation: Review of inflammation severity, metaplasia, dysplasia, or malignancy to guide clinical management and surveillance
- Monitoring frequency: Annual surveillance biopsy may be considered for patients with extensive intestinal metaplasia, atrophy, or dysplasia
Fasting Required?
- No fasting required specifically for second opinion slide review, as this is a laboratory examination of previously collected biopsy tissue
- Note: If original biopsy collection requires repeat endoscopy, then fasting is required 6-8 hours before procedure
- Medication considerations: Proton pump inhibitors and bismuth compounds should be discontinued 2 weeks before biopsy for accurate H. pylori detection
- Antibiotic timing: Any recent antibiotic use within 4 weeks may suppress H. pylori and reduce detection sensitivity; document timing in clinical history
- Patient preparation for endoscopy (if needed): Nothing by mouth from midnight; remove dentures and jewelry; arrange transportation
- Specimen handling: Ensure biopsies are promptly fixed in formalin and properly labeled with site location for accurate pathologic interpretation

How our test process works!